Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apilimod + rituximab
- Development stage
- Unknown
- Lead developer
- AI Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (apilimod), Intravenous (rituximab), Subcutaneous (rituximab/rituximab Hyaluronidase)
01
Overview
apilimod + rituximab is an investigational combination therapy under clinical development for the treatment of B-cell non-Hodgkin lymphoma (B-NHL) and other B-cell malignancies. Apilimod (LAM-002A) is a first-in-class, oral small molecule inhibitor of the lipid kinase PIKfyve, which leads to disruption of lysosomal homeostasis and induces cytotoxicity in B-cell lymphoma models. Rituximab is a monoclonal antibody targeting the CD20 antigen on B cells, mediating B-cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity. In preclinical and early clinical trials, the combination has demonstrated synergistic anti-tumor activity: apilimod enhances direct B-cell lymphoma cytotoxicity, while rituximab promotes immune-mediated clearance of malignant B cells. The combination is being investigated in phase 1/2 cohorts for efficacy, safety, and pharmacokinetics.
- Other names
- apilimod mesylate + rituximabLAM-002A + rituximab
02
Targets
PIKFYVE (Phosphoinositide kinase, FYVE-type zinc finger containing enzyme)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on apilimod + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apilimod + rituximab.